

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: BioMark Diagnostics Inc. (the "Issuer").

Trading Symbol: BUX

Number of Outstanding Listed Securities: 67,015,119

Date: May 1st, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early, accurately and cost effectively.

2. Provide a general overview and discussion of the activities of management.
- **Management continues to raise capital through private placement, family funds and other strategic sources to support completion of clinical trials studies, regulatory submission and commercialization of its technology platform. Management has been working on numerous non-dilutive financing with various government institutions and strategic investors across Canada and United States.**
 - **On April 16th, 2019, BioMark announced that it successfully closed the private placement as per new release on April 9th, 2019. The Issuer issued 2,000,000 units at a price of CAD \$0.10 per unit for gross proceeds of \$ 200,000. Each unit consists of one common share of the Issuer and one share purchase warrant.**
 - **On April 17th, 2019, BioMark was pleased to announce that its application entitled “Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma”, submitted to the Collaborative Health Research Projects funding opportunity, had been approved. The application was Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) and in collaboration with the Social Sciences and Humanities Research Council (SSHRC). The funding is approximately for \$750,000. BioMark is the industrial partner on the grant.**
 - **The manuscript entitled “Predictive value and clinical significance of increased SSAT-1 activity in healthy adults”, which was submitted to Future Science OA, has been accepted on April 24th, 2019. The manuscript will be published later in early June 2019.**
 - **Discovery paper in the use of new metabolites in conjunction with Amantadine assay to increase tissue specificity is being written and a completed paper is expected for a team review by mid-May. Our intent is to have it published in a peer reviewed journal as soon as possible.**

About CHRP

Collaborative Health Research Projects (CHRP) is a joint initiative between the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Social Sciences and Humanities Research Council of Canada (SSHRC). CHRP grants support focused, interdisciplinary, collaborative research projects involving any field of the natural sciences or engineering and any field of the health sciences.

Proposed research projects should be innovative, with a strong focus on knowledge translation, and lead to health benefits for Canadians, more effective health services and/or economic development in health-related areas.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.
Not applicable.
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
The Issuer continues to file trademark and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.
10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.
Not applicable.
11. Report on any labour disputes and resolutions of those disputes if applicable.
Not applicable.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
Not applicable.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
Not applicable.
14. Provide details of any securities issued and options or warrants granted.
On April 16th, 2019, the Issuer issued 2,000,000 units at a price of CAD \$0.10 per unit for gross proceeds of \$ 200,000. Each unit consists of one common share of the Issuer and one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of the Issuer at \$0.20 per share for a period of two years from the closing date of the private placement, subject to an acceleration clause.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Form 51-102F1 Management's Discussion & Analysis Annual Report for the Year Ended March 31, 2018.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 1st, 2019.

Rashid Ahmed BUX
Name of Director or Senior
Officer

"Rashid Ahmed Bux"
Signature

President & CEO
Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer		End	YY/MM/DD
BioMark Diagnostics Inc.		April, 2019	2019/05/01
Issuer Address			
165-10551 Shellbridge Way			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Richmond, BC, V6X 2W8		N/A	(604) 370-0779
Contact Name		Contact Position	Contact Telephone No.
Rashid Ahmed Bux		CEO	(604) 370-0779
Contact Email Address		Web Site Address	
info@biomarkdiagnostics.com		www.biomarkdiagnostics.com	